ESH MM 2018 | Vaccines to prevent progression or relapse in multiple myeloma

Ann van de Velde

Ann van de Velde, MD, PhD, from Antwerp University Hospital, Antwerp, Belgium discusses the use of an autologous dendritic cell vaccination for multiple myeloma (MM). In addition, Dr van de Velde highlights the value of developing the vaccine, including the benefits of a low toxicity and short preparation time, and covers its cost relative to other novel treatments. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Share this video